1. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy
- Author
-
Ana Giménez-Arnau, E. Rizova, Shyamalie Jayawardena, Tove Agner, Zafer E. Ozturk, Åke Svensson, Marius Ardeleanu, Annalisa Patrizi, Petr Arenberger, Laurent Eckert, Marie L A Schuttelaar, Marjolein S. de Bruin-Weller, Andrew Pink, Silvia Ferrucci, Audrey Nosbaum, Pierre Paul Roquet-Gravy, and Public Health Research (PHR)
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Dermatology ,Comorbidity ,Systemic therapy ,Severity of Illness Index ,Dermatitis, Atopic ,systemic therapy ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Quality of life (healthcare) ,Cost of Illness ,Adrenal Cortex Hormones ,medicine ,Prevalence ,Humans ,Prospective Studies ,Treatment history ,Health policy ,Disease burden ,Aged ,Atopic dermatitis ,030203 arthritis & rheumatology ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,body regions ,quality of life ,patient-reported outcomes ,Baseline characteristics ,Cyclosporine ,Observational study ,Female ,Dermatologic Agents ,business - Abstract
Background: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions.Methods: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics.Results: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and >= 1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator's Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale.Conclusions: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.
- Published
- 2021